EMA · European Union
sutimlimab — EMA regulatory status
sutimlimab (ENJAYMO) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA approved.
Status snapshot
- Status
- EMA approved
- Brand
- ENJAYMO
- Mechanism
- Complement C1s inhibitor
- Target
- Complement C1s subcomponent
- Structured fields
- 5
Pharmacology context used for competitive intelligence: Complement C1s inhibitor. Target: Complement C1s subcomponent. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: approved.
Linked evidence on this spoke: 0 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | approved | — | Evidence |
Related hubs
FAQ
What is the EMA approval status of sutimlimab?
sutimlimab currently shows EMA approved in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get sutimlimab regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.